Get started
EQUINOR (EQNR) | Important Signs For Further Growth!Hi, Equinor ASA , an energy company, explores for, produces, transports, refines and markets petroleum and petroleum-derived products, and other forms of energy in Norway and internationally. Fundamental pros: 1. Trading below its fair value. 2. Good PE and PEG ratio. 3. Earnings are forecasted to grow. 4. A lot of insider buying. Technical pros: The correction, which started at the end of 2018, has started to show some positive signs for further growth. 1. The price has made a breakout from the down-trendline aka counter-trendline. Counter-trendlines breakouts are a pretty powerful tool to follow, especially when we have a really strong starting platform as Equinor has it at the moment. 2. Actually, the price made a breakout a couple of weeks ago and it has already retest it and again, it got a rejection upwards - the trendline which worked previously as resistance becomes support. 3. The trendline starts to work as support and there are also Weekly EMA 200 and Monthly EMA 50 which also should act as support levels. So, we have a pretty solid support level under the current price which is very good considering the breakthrough the counter-trendline. To show that mentioned "strong starting platform", we have to dig into the Monthly timeframe: The price got a pretty amazing rejection from a super-strong price level, it stays between ~150-160. A lot of criteria matched almost perfectly (strong support, AB=CD, Channel projection, Fibonacci golden ratio, EMA) and the rejection formed the strongest candlestick pattern ever lived (massive hype :D) - Monthly timeframe "Morning Star" has formed around the strong area! It depends on your investment horizon but the good entry should stay between the current price, 173, to 160 (in case it makes a tiny correction) but as said previously - luckily we have strong support just below the current price. The first target is around the psychological number 200 which should offer us about 17-20 percent profit. Do your own research and if this matching with mine then you are ready to go! Please, take a second and support my effort by hitting the "LIKE" button, it is my only FEE from You! Best regards, Vaido
OSL:EQNRLong
by VaidoVeek
LERØY SEAFOOD (LSG) | Strong Fundamentally & Technically!Hi, Lerøy Seafood Group produces, processes, markets, and distributes fresh, frozen, and smoked seafood products in Norway. It shows pretty good value numbers, it is way undervalued, insiders (CEO) have bought the stock recently (actually yesterday) and etc. Fundamentally, Lerøy Seafood looks quite good and most importantly, technically as well. There is a perfect area where you can invest or reinvest to Lerøy Seafood, the area consists of: 1) Weekly EMA200 2) Monthly EMA50 3) The round number 50 4) Channel projection 5) 2x AB=CD 6) Fibonacci Extensions 7) Fibonacci retracement 38%, pulled from all-time low to all-time high. 8) The trendline since 2012, historically, it is worked perfectly as support 9) 2016 high They all should work as support levels, adding these criteria together gives us a strong support area between 48 - 52.5 , which is also technically a good area to buy Lerøy Seafood. The first target stays around 60 which is approximately +20%. Do your own research and if this matching with mine then you are ready to go! Please, take a second and support my effort by hitting the "LIKE" button, it is my only FEE from You! Best regards, Vaido
OSL:LSGLong
by VaidoVeek
1
PCI Biotech $PCIB.OL top 10 hot nordic stocks @veckansaffarer www.va.se finansavisen.no PCI Biotech OSL:PCIB is a biopharmaceutical company focusing on development and commercialisation of novel therapeutic solutions for improved treatment of cancer patients through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that can be used to unlock the true potential of a wide array of therapeutic modalities. The company is applying PCI to three distinct anticancer paradigms: • fimaCHEM – enhancement of chemotherapeutics for localised treatment of cancer • fimaVACC – enhanced T-cell induction for therapeutic vaccination • fimaNAc – nucleic acid therapeutics delivery The company’s lead fimaCHEM programme consists of a pivotal clinical study with registration intent of Amphinex® in bile duct cancer, an orphan indication with a high-unmet need and without approved products. Clinical proof-of-concept has been achieved in the fimaVACC programme, which applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines. The fimaNAc programme utilises the triggered endosomal release to provide effective intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising class of therapeutics.
OSL:PCIB
by savepiginvest
Bakkafrost, at the top of everything?Bakkafrost looks to be closing to the top of everything, IF previous pattern repeats itself. From just half a year ago Bakkafrost could be bought at around 440 NOK followed by a steady rise to a current 640 NOK. This is a staggering 50% increase in just half a year. That alone is not the only factor Bakkafrost has against a further rise. We also see that if the Impulse Elliot Waves repeats itself we are close to an A,B,C elliot correction. Or even an A,B,C,D correction. But time will show. Also Bakkafrost is getting very close to the top of the parallel channel its been impulsing in for close to a year now. If it breaks the channel, thats another case. But I find that unlikely but still possible. So basing it on previous Elliot Waves. We see that impulse wave 1,2,3,4 and 5 was completed. Then the Elliot A,B to C was completed. Immediately after that Bakkafrost continued into a new set of impulse waves, 1,2,3,4 and the fifth close to completing. Still some more room for a further rise, but again, if the pattern repeats itself, we are likely to soon see the correction in Bakkafrost. I am short
OSL:BAKKAShort
by Stilster
BerGenBio $BGBIO.OL rallies amid Norwegian biotech optimismBerGenBio OSL:BGBIO is a norwegian clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers. The stock is currently in a short term uptrend that could provide a new test of important resistance, where a breakout to the upside could trigger a powerful buy signal. Sponsored analyst summary: www.trinitydelta.org Twitter: twitter.com Investor Relations: www.bergenbio.com
OSL:BGBIOLong
by savepiginvest
Possible horizontal development Another attempt to identify the development for the stock in which I hold my largest position. This multi disciplinary "national treasure" company, with very long lines back to the original Fred. Olsen-company, is ideal for me to practice on. It´s stable development trends is very forgiving for the rookie eye to experiment with. Now, a possible horizontal movement could be under development after a long and steady climb. I will make an attempt at possible future developments based on this preschool sketch later :)
OSL:BONHRLong
by Toreaxx